

# Medical Issues III Panel

---

## Series Editors:

### **Bradley A. Boucher, Pharm.D., FCCP, FNAP, MCCM, BCPS**

*Professor of Clinical Pharmacy and Translational Science  
Associate Dean for Strategic Initiatives and Operations  
College of Pharmacy  
University of Tennessee Health Science Center  
Memphis, Tennessee*

### **Curtis E. Haas, Pharm.D., FCCP**

*Director of Pharmacy  
University of Rochester Medical Center  
Rochester, New York*

## Faculty Panel Chair:

### **Ishaq Lat, Pharm.D., FCCP, BCPS, BCCCP, BCPS**

*Associate Director-Clinical Services  
Critical Care Clinical Pharmacy Specialist  
Department of Pharmacy  
Rush University Medical Center  
Chicago, Illinois*

## **PATIENTS WITH IMMUNOCOMPROMISE IN THE ICU**

### Authors

#### **Mark H. Pangrazzi, Pharm.D., BCCCP**

*Clinical Pharmacy Specialist-Critical Care  
Department of Pharmacy Services  
Detroit Medical Center, Sinai-Grace Hospital  
Detroit, Michigan*

#### **Ryan P. Mynatt, Pharm.D.**

*Clinical Pharmacist Specialist, Infectious Diseases  
Detroit Receiving Hospital, Detroit Medical Center  
Royal Oak, Michigan*

### Reviewers

#### **Stephanie Bass, Pharm.D., BCPS, BCCCP**

*Medical ICU Clinical Pharmacist  
Pharmacy Department  
Cleveland Clinic  
Cleveland, Ohio*

#### **David J. Ritchie, Pharm.D., BCPS, AQ-ID**

*Professor of Pharmacy Practice  
St. Louis College of Pharmacy  
Clinical Pharmacy Specialist-Infectious Diseases  
Pharmacy Department  
Barnes-Jewish Hospital  
St. Louis, Missouri*

### **Zachary R. Smith, Pharm.D., BCPS, BCCCP**

*Clinical Pharmacist-Critical Care  
Pharmacy Department  
Henry Ford Hospital  
Detroit, Michigan*

### **Shereen Ahmed Dasuqi, MSc. Pharm., BCPS, BCCCP**

*Critical Care Clinical Pharmacist  
Department of Pharmacy Services  
King Saud University Medical City  
Riyadh, Saudi Arabia*

## **END-OF-LIFE CARE**

### Authors

#### **Marilyn N. Bulloch, Pharm.D., FCCM, BCPS**

*Associate Clinical Professor of Pharmacy Practice  
Department of Pharmacy Practice  
Auburn University Harrison School of Pharmacy  
Tuscaloosa, Alabama*

#### **Jim E. Winegardner, Pharm.D., BCPS**

*Clinical Instructor  
Department of Pharmacology, School of Medicine  
Oakland University William Beaumont School  
of Medicine  
Rochester Hills, Michigan*

### Reviewers

#### **Lindsay Pell Ryder, Pharm.D., BCPS**

*Specialty Practice Pharmacist-Critical Care  
Pharmacy Department  
The Ohio State University Wexner Medical Center  
Columbus, Ohio*

#### **Raul A. Santiago, Pharm.D., BCPS**

*Clinical Pharmacy Specialist  
Pharmacy Department  
Brigham and Women's Faulkner Hospital  
Boston, Massachusetts*

#### **Michael J. McQuade, Pharm.D., BCPS**

*Clinical Pharmacist  
Department of Pharmacy  
CHI Health, St. Elizabeth  
Lincoln, Nebraska*

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Medical Issues III chapters:

**Ralph H. Raasch, Pharm.D., FCCP, BCPS**

*Associate Professor of Pharmacy (retired)*  
Division of Practice Advancement and Clinical Education  
Eshelman School of Pharmacy  
The University of North Carolina at Chapel Hill  
Chapel Hill, North Carolina

**Emilie L. Karpiuk, Pharm.D., BCPS**

*Oncology Pharmacist*  
Department of Pharmacy  
Froedtert Hospital  
Milwaukee, Wisconsin

## DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

**Consultancies:** Abigail D. Antigua (Florida Society of Health-Systems Pharmacists, Society of Critical Care Medicine); Marilyn N. Bulloch (Alabama Medicaid DUR Board); Ryan P. Mynatt (Theravance)

**Stock Ownership:**

**Royalties:**

**Grants:** Matthew A. Wanat (Bristol-Myers Squibb)

**Honoraria:** Abigail D. Antigua (FSHP); Mark H. Pangrazzi (Pfizer/Bristol Myers Squibb)

**Other:**

**Nothing to disclose:** Shereen Ahmed Dasuqi; Stephanie Bass; Scott T. Benken; Gabrielle Gibson; Susan E. Hamblin; Serena A. Harris; Sarah Livings; Michael J. McQuade; Megan E. Musselman; Gourang Patel; Megan A. Rech; Brianne M. Ritchie; David J. Ritchie; Kelli A. Rumbaugh; Lindsay P. Ryder; Raul A. Santiago; Zach R. Smith; William R. Vincent, III; Matthew R. Wanek; Jim E. Winegardner; Michael E. Wright, II

**ROLE OF BPS:** The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. CCSAP has been approved by BPS for use in BCCCP recertification. Information about the BPS recertification process is available [online](#).

Questions regarding BCCCP recertification should be directed to:

[Board of Pharmacy Specialties](#)  
2215 Constitution Avenue NW  
Washington, DC 20037  
(202) 429-7591